Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Lithuania a prime location for data centersVYTIS MALECKAS
LITHUANIA PRIME LOCATION FOR DATA CENTERS
SUMMARY
• Stable Power Supply
• Resilient Power Infrastructure on Site
• Renewable Energy
• Fiber Network
• Nordic Climate and Cooling Solutions
• Secure Location
• Competitive Talent Pool
• Leading ICT Infrastructure
• Financial Incentives
• Accessibility
MISSION
Ensure that by 2020 a broader and more varied set of users discovers and accesses the existing and emerging e-Infrastructure capacity and e-Science Services
PharmaLedger Ethical and Legal InventoryPharmaLedger
The D5.1 PharmaLedger Ethical and Legal Inventory deliverable sets up the legal framework for the PharmaLedger project and presents the legal and ethical requirements to be applied in the design and execution of the platform. This document serves as a background for WP5 to perform the upcoming detailed ethical and legal study following the terms and conditions from the Grant Agreement.
As the goal of the PharmaLedger project is to provide a widely trusted platform that supports the design and adoption of blockchain-enabled healthcare solutions while accelerating the delivery of innovation that benefits the entire ecosystem, from manufacturers to patients, the project is operating in saturated and highly regulated markets. Therefore, it is critical to identify the legal challenges in the early stage of designing the platform. To that end, this document serves two purposes: i) setting up the legal and ethical framework that applies to PharmaLedger and identifying the legal and ethical requirements for which compliance is mandatory; ii) raising awareness, especially about key standing items on every IT developer’s risk agenda – privacy and data security.
This document is organised across three key themes: privacy and data protection, clinical trials, and the pharmaceutical supply chain. It provides high-level guidance on ethics and the laws and regulations on privacy, data protection, security, confidentiality, clinical trials, drug development, manufacturing, and distribution. As PharmaLedger is sponsored by the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under the European Union’s Horizon 2020 programme, the legal framework in this deliverable is limited to the laws, regulations, and other normative acts applicable on the EU/EEA territory. Compliance issues must always be considered on a country-by-country basis due to many aspects being regulated only at the national level – an analysis that requires extensive knowledge of the specific country’s legislative processes and the official language of that country. Therefore, this document should by no means be interpreted as an exhaustive elaboration of the applicable regulatory and legal requirements.
1) Hepatitis E virus (HEV) infection has emerged as an important public health issue in Europe, with over 21,000 cases reported between 2005-2015 across EU/EEA countries.
2) Surveillance systems and case definitions for HEV vary between countries, but most (20/30) now have specific national surveillance for HEV in place.
3) The majority (98%) of HEV cases in Europe are now locally acquired rather than travel-associated, and over half of all cases are diagnosed in hospitals.
Oxford Internet Institute - Twitter predicts epidemicsPatty Kostkova
Can Twitter provide an Early Warning function for the next Flu Pandemics?
OII blog: http://blogs.oii.ox.ac.uk/policy/can-twitter-provide-an-early-warning-function-for-the-next-flu-pandemic/
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Lithuania a prime location for data centersVYTIS MALECKAS
LITHUANIA PRIME LOCATION FOR DATA CENTERS
SUMMARY
• Stable Power Supply
• Resilient Power Infrastructure on Site
• Renewable Energy
• Fiber Network
• Nordic Climate and Cooling Solutions
• Secure Location
• Competitive Talent Pool
• Leading ICT Infrastructure
• Financial Incentives
• Accessibility
MISSION
Ensure that by 2020 a broader and more varied set of users discovers and accesses the existing and emerging e-Infrastructure capacity and e-Science Services
PharmaLedger Ethical and Legal InventoryPharmaLedger
The D5.1 PharmaLedger Ethical and Legal Inventory deliverable sets up the legal framework for the PharmaLedger project and presents the legal and ethical requirements to be applied in the design and execution of the platform. This document serves as a background for WP5 to perform the upcoming detailed ethical and legal study following the terms and conditions from the Grant Agreement.
As the goal of the PharmaLedger project is to provide a widely trusted platform that supports the design and adoption of blockchain-enabled healthcare solutions while accelerating the delivery of innovation that benefits the entire ecosystem, from manufacturers to patients, the project is operating in saturated and highly regulated markets. Therefore, it is critical to identify the legal challenges in the early stage of designing the platform. To that end, this document serves two purposes: i) setting up the legal and ethical framework that applies to PharmaLedger and identifying the legal and ethical requirements for which compliance is mandatory; ii) raising awareness, especially about key standing items on every IT developer’s risk agenda – privacy and data security.
This document is organised across three key themes: privacy and data protection, clinical trials, and the pharmaceutical supply chain. It provides high-level guidance on ethics and the laws and regulations on privacy, data protection, security, confidentiality, clinical trials, drug development, manufacturing, and distribution. As PharmaLedger is sponsored by the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under the European Union’s Horizon 2020 programme, the legal framework in this deliverable is limited to the laws, regulations, and other normative acts applicable on the EU/EEA territory. Compliance issues must always be considered on a country-by-country basis due to many aspects being regulated only at the national level – an analysis that requires extensive knowledge of the specific country’s legislative processes and the official language of that country. Therefore, this document should by no means be interpreted as an exhaustive elaboration of the applicable regulatory and legal requirements.
1) Hepatitis E virus (HEV) infection has emerged as an important public health issue in Europe, with over 21,000 cases reported between 2005-2015 across EU/EEA countries.
2) Surveillance systems and case definitions for HEV vary between countries, but most (20/30) now have specific national surveillance for HEV in place.
3) The majority (98%) of HEV cases in Europe are now locally acquired rather than travel-associated, and over half of all cases are diagnosed in hospitals.
Oxford Internet Institute - Twitter predicts epidemicsPatty Kostkova
Can Twitter provide an Early Warning function for the next Flu Pandemics?
OII blog: http://blogs.oii.ox.ac.uk/policy/can-twitter-provide-an-early-warning-function-for-the-next-flu-pandemic/
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
This document lists over 50 grants that CF Consulting has submitted and/or managed with EU and other funding support over several decades. The grants span a wide range of topics including health, neuroscience, biomedicine, engineering and more. Many were coordinated by Italian research institutions with international partnerships. CF Consulting has helped organizations secure millions of euros in funding for collaborative projects.
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including the number of applicants and funding requested from Jordan compared to other Mediterranean partner countries. Opportunities for future cooperation are also outlined, such as new topics in FP7 calls and instruments to strengthen collaboration.
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including the number of applicants and funding requested from Jordan compared to other Mediterranean partner countries. Opportunities for future cooperation are also outlined, such as new topics in FP7 calls and support for networking activities.
SRTD Final Conference
Session 1: Research
EU JORDAN S&T Cooperation: Jordan's participation in FP7
Germana Topolovec
Trade, Economic Affairs & Private Sector Development
Delegation of the European Union to Jordan
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including areas of focus, funding opportunities, and Jordan's participation compared to other Mediterranean partner countries. Key points include the establishment of an EU-Jordan S&T agreement in 2009, Jordan receiving over €2.5 million in funding for 34 main listed projects between 2007-2010, and opportunities for increased Jordanian participation in FP7 programs going forward.
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including Jordanian participation levels. Key points include Jordan signing an EU-Jordan S&T agreement in 2009, Jordanian researchers and organizations receiving over €2.5 million in FP7 funding between 2007-2010, and opportunities for increased future cooperation.
CV - Toon POPPE - long - 10 April 14 - finalToon poppe
This document provides a summary of Antoine Poppe's education and professional experience. It shows that he has a diverse background, obtaining degrees in economics, business administration, and European law and economics. He has worked in academia, consulting, executive search, and general management roles in various industries. More recently, he has focused on telemedicine and developing technologies for remote patient monitoring.
This document provides the agenda for a two-day forum on justice and anti-corruption reforms in Moldova organized by LRCM and IPRE. The event will have panels on combating corruption, investigating corruption, verifying assets, justice reform, judicial independence, and accessibility and efficiency of justice. Speakers will include government officials, anti-corruption experts, and representatives from the EU, CoE, and other countries. The forums aims to discuss reforms, lessons learned, and increasing transparency, efficiency, and public confidence in these areas.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
The document discusses the activities and results of the JSO-ERA project, which aims to enhance Ukraine's integration into the EU Research Area. Some key points:
1) The project has provided knowledge, recognition of Ukrainian research communities and SMEs, partnerships, and networks in priority areas like food and agriculture.
2) It has organized various events like conferences, training visits, and brokerage events to share knowledge and facilitate collaboration.
3) Initial results include partnerships in 5 FP7 projects related to food and agriculture, as well as involvement in other initiatives like ERA-Wide. However, more remains to be done to fully achieve integration with the ERA.
This document discusses new approaches to improving access to HIV testing, particularly among men who have sex with men (MSM) in Europe. It notes that MSM account for over 40% of new HIV diagnoses in the EU and testing rates are low with high rates of late diagnosis. The document describes how mobile apps and social media platforms can potentially increase HIV testing uptake among MSM through large-scale, low-cost outreach. It provides examples of partnerships between health organizations and apps like Grindr, Hornet, and PlanetRomeo to promote initiatives like European HIV Testing Week through targeted push notifications and banners. Guidance is being developed on effectively using digital platforms and social media for STI/HIV prevention among MSM
EnviCrimeNet Intelligence Project on Environmental Crimeecogisements_org
This document provides a preliminary report on environmental crime in Europe from the EnviCrimeNet Intelligence Project on Environmental Crime (IPEC). The report finds that environmental crimes cover a wide range of offenses including those related to chemicals, endangered species, energy, pollution, waste, and others. Many jurisdictions have laws to protect the environment but not all violations are considered criminal, and environmental crimes can be difficult to detect as they often lack immediate victims. Through surveys, interviews, and research, IPEC aims to better understand the issues around environmental crime in Europe and fill intelligence gaps to help address related threats.
This document summarizes several articles from the Volta newsletter. It discusses a European project called DESSI that developed a decision-making methodology and online tool to help policymakers choose appropriate security options while considering factors beyond just technology. It also mentions a large-scale citizen consultation in France on energy policy that used the World Wide Views method. Finally, it provides brief updates on upcoming conferences related to science, technology and innovation policy.
This document summarizes feedback from the 15th National Microbiology Focal Points meeting. It discusses ECDC's microbiology web portal and resources available, including the NMFP forum, EULabServe repository for laboratory testing services, microbiology coordination newsletters, and surveys on topics like national capacity for whole genome sequencing. It also covers the EULabCap project for indicator scoring and reporting of diagnostic capabilities and participation in European reference laboratory networks. NMFP members are asked to provide feedback on indicator clarity and updates.
This document provides an analysis of evidence from social innovation good practices across the EU that examine whether technology-based services can support long-term care challenges in home care. It begins with acknowledgments and preface sections. The document then provides an executive summary and introduces the topics of long-term care, the increasing demand for it in Europe, the role of families and informal carers in provision of long-term care, and the increasing role of migrant care workers. It examines the current state of ICT-based solutions that could support informal carers and the research and policy contexts regarding these solutions.
Tue 14 jun 09 40 opening address - digital agenda peteris zilgalvis3GDR
The document discusses the Digital Agenda for Europe and the European Innovation Partnerships. It aims to achieve a transparent and innovative health market through defining eHealth, describing EC instruments like FP7, and discussing initiatives like the Digital Agenda for Europe and the European Innovation Partnership on Active Healthy Ageing. The Partnership aims to add 2 healthy years to the average lifespan in the EU by 2020 through prevention, integrated health/social care for the elderly, and independent living support.
Cv toon poppe - long - 10 april 14 - finalToon poppe
This document provides a summary of Antoine Poppe's education and professional experience from 1958 to 2012. It details his academic background which includes degrees from the University of Leuven in Applied Economics and the University of Illinois in Business Administration. It then outlines his extensive professional experience over several decades working in roles such as research, management, consulting, and establishing technology companies focused on industries like steel, oil, construction, telecommunications, and telemedicine. The document demonstrates Poppe's long career developing businesses and bringing technological innovations to markets across Europe, North America, and the Middle East.
Gender Balance in EU and a Case Report of an EU Funded Project, by E. KaldoudiWiMBE_IFMBE
Eleni Kaldoudi, Gender Balance in EU and a Case Report of an EU Funded Project, Invited Talk, Special Session on Women in Medical and Biological Engineering, MEDICON 2016, Paphos, Cyprus, 2 April 2016
Gender Balance in EU and a Case Report of an EU Funded ProjectCARRE project
The document summarizes statistics from EU reports on gender in research and innovation. It finds that while women represent 40-60% of PhD graduates across EU countries, they remain underrepresented in engineering and computing. There is also a gender imbalance in academic careers, with fewer women achieving full professor roles. The document also describes the CARRE project, an EU-funded project on cardiorenal disease with efforts for gender balance among work package leaders, task leaders, and project participants.
Carbapenem-resistant Acinetobacter baumannii poses a significant threat in healthcare settings across Europe. It can cause serious infections that are difficult to treat due to limited antibiotic options. The number of countries reporting spread and endemicity of carbapenem-resistant A. baumannii has increased in recent years. Increased detection and control efforts are needed to prevent it from becoming endemic in more European regions and healthcare facilities.
The document discusses the global spread of the mcr-1 gene, which confers plasmid-mediated colistin resistance in Enterobacteriaceae. This poses a substantial public health risk as it limits treatment options for multidrug-resistant infections. Options for response include improved detection of mcr-1 via laboratory methods like PCR and whole genome sequencing, enhanced surveillance programs, infection control measures in healthcare settings, antimicrobial stewardship, and reducing colistin use in animals to prevent further spread. A One Health approach combining human and veterinary medicine is needed to monitor mcr-1 in food and the environment.
More Related Content
Similar to ECDC ESAC-Net update. Klaus Weist (ECDC)
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
This document lists over 50 grants that CF Consulting has submitted and/or managed with EU and other funding support over several decades. The grants span a wide range of topics including health, neuroscience, biomedicine, engineering and more. Many were coordinated by Italian research institutions with international partnerships. CF Consulting has helped organizations secure millions of euros in funding for collaborative projects.
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including the number of applicants and funding requested from Jordan compared to other Mediterranean partner countries. Opportunities for future cooperation are also outlined, such as new topics in FP7 calls and instruments to strengthen collaboration.
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including the number of applicants and funding requested from Jordan compared to other Mediterranean partner countries. Opportunities for future cooperation are also outlined, such as new topics in FP7 calls and support for networking activities.
SRTD Final Conference
Session 1: Research
EU JORDAN S&T Cooperation: Jordan's participation in FP7
Germana Topolovec
Trade, Economic Affairs & Private Sector Development
Delegation of the European Union to Jordan
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including areas of focus, funding opportunities, and Jordan's participation compared to other Mediterranean partner countries. Key points include the establishment of an EU-Jordan S&T agreement in 2009, Jordan receiving over €2.5 million in funding for 34 main listed projects between 2007-2010, and opportunities for increased Jordanian participation in FP7 programs going forward.
The document discusses Jordan's participation in the European Union's Seventh Framework Programme for Research and Technological Development (FP7). It provides an overview of EU-Jordan cooperation in science and technology under FP7, including Jordanian participation levels. Key points include Jordan signing an EU-Jordan S&T agreement in 2009, Jordanian researchers and organizations receiving over €2.5 million in FP7 funding between 2007-2010, and opportunities for increased future cooperation.
CV - Toon POPPE - long - 10 April 14 - finalToon poppe
This document provides a summary of Antoine Poppe's education and professional experience. It shows that he has a diverse background, obtaining degrees in economics, business administration, and European law and economics. He has worked in academia, consulting, executive search, and general management roles in various industries. More recently, he has focused on telemedicine and developing technologies for remote patient monitoring.
This document provides the agenda for a two-day forum on justice and anti-corruption reforms in Moldova organized by LRCM and IPRE. The event will have panels on combating corruption, investigating corruption, verifying assets, justice reform, judicial independence, and accessibility and efficiency of justice. Speakers will include government officials, anti-corruption experts, and representatives from the EU, CoE, and other countries. The forums aims to discuss reforms, lessons learned, and increasing transparency, efficiency, and public confidence in these areas.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
The document discusses the activities and results of the JSO-ERA project, which aims to enhance Ukraine's integration into the EU Research Area. Some key points:
1) The project has provided knowledge, recognition of Ukrainian research communities and SMEs, partnerships, and networks in priority areas like food and agriculture.
2) It has organized various events like conferences, training visits, and brokerage events to share knowledge and facilitate collaboration.
3) Initial results include partnerships in 5 FP7 projects related to food and agriculture, as well as involvement in other initiatives like ERA-Wide. However, more remains to be done to fully achieve integration with the ERA.
This document discusses new approaches to improving access to HIV testing, particularly among men who have sex with men (MSM) in Europe. It notes that MSM account for over 40% of new HIV diagnoses in the EU and testing rates are low with high rates of late diagnosis. The document describes how mobile apps and social media platforms can potentially increase HIV testing uptake among MSM through large-scale, low-cost outreach. It provides examples of partnerships between health organizations and apps like Grindr, Hornet, and PlanetRomeo to promote initiatives like European HIV Testing Week through targeted push notifications and banners. Guidance is being developed on effectively using digital platforms and social media for STI/HIV prevention among MSM
EnviCrimeNet Intelligence Project on Environmental Crimeecogisements_org
This document provides a preliminary report on environmental crime in Europe from the EnviCrimeNet Intelligence Project on Environmental Crime (IPEC). The report finds that environmental crimes cover a wide range of offenses including those related to chemicals, endangered species, energy, pollution, waste, and others. Many jurisdictions have laws to protect the environment but not all violations are considered criminal, and environmental crimes can be difficult to detect as they often lack immediate victims. Through surveys, interviews, and research, IPEC aims to better understand the issues around environmental crime in Europe and fill intelligence gaps to help address related threats.
This document summarizes several articles from the Volta newsletter. It discusses a European project called DESSI that developed a decision-making methodology and online tool to help policymakers choose appropriate security options while considering factors beyond just technology. It also mentions a large-scale citizen consultation in France on energy policy that used the World Wide Views method. Finally, it provides brief updates on upcoming conferences related to science, technology and innovation policy.
This document summarizes feedback from the 15th National Microbiology Focal Points meeting. It discusses ECDC's microbiology web portal and resources available, including the NMFP forum, EULabServe repository for laboratory testing services, microbiology coordination newsletters, and surveys on topics like national capacity for whole genome sequencing. It also covers the EULabCap project for indicator scoring and reporting of diagnostic capabilities and participation in European reference laboratory networks. NMFP members are asked to provide feedback on indicator clarity and updates.
This document provides an analysis of evidence from social innovation good practices across the EU that examine whether technology-based services can support long-term care challenges in home care. It begins with acknowledgments and preface sections. The document then provides an executive summary and introduces the topics of long-term care, the increasing demand for it in Europe, the role of families and informal carers in provision of long-term care, and the increasing role of migrant care workers. It examines the current state of ICT-based solutions that could support informal carers and the research and policy contexts regarding these solutions.
Tue 14 jun 09 40 opening address - digital agenda peteris zilgalvis3GDR
The document discusses the Digital Agenda for Europe and the European Innovation Partnerships. It aims to achieve a transparent and innovative health market through defining eHealth, describing EC instruments like FP7, and discussing initiatives like the Digital Agenda for Europe and the European Innovation Partnership on Active Healthy Ageing. The Partnership aims to add 2 healthy years to the average lifespan in the EU by 2020 through prevention, integrated health/social care for the elderly, and independent living support.
Cv toon poppe - long - 10 april 14 - finalToon poppe
This document provides a summary of Antoine Poppe's education and professional experience from 1958 to 2012. It details his academic background which includes degrees from the University of Leuven in Applied Economics and the University of Illinois in Business Administration. It then outlines his extensive professional experience over several decades working in roles such as research, management, consulting, and establishing technology companies focused on industries like steel, oil, construction, telecommunications, and telemedicine. The document demonstrates Poppe's long career developing businesses and bringing technological innovations to markets across Europe, North America, and the Middle East.
Gender Balance in EU and a Case Report of an EU Funded Project, by E. KaldoudiWiMBE_IFMBE
Eleni Kaldoudi, Gender Balance in EU and a Case Report of an EU Funded Project, Invited Talk, Special Session on Women in Medical and Biological Engineering, MEDICON 2016, Paphos, Cyprus, 2 April 2016
Gender Balance in EU and a Case Report of an EU Funded ProjectCARRE project
The document summarizes statistics from EU reports on gender in research and innovation. It finds that while women represent 40-60% of PhD graduates across EU countries, they remain underrepresented in engineering and computing. There is also a gender imbalance in academic careers, with fewer women achieving full professor roles. The document also describes the CARRE project, an EU-funded project on cardiorenal disease with efforts for gender balance among work package leaders, task leaders, and project participants.
Similar to ECDC ESAC-Net update. Klaus Weist (ECDC) (20)
Carbapenem-resistant Acinetobacter baumannii poses a significant threat in healthcare settings across Europe. It can cause serious infections that are difficult to treat due to limited antibiotic options. The number of countries reporting spread and endemicity of carbapenem-resistant A. baumannii has increased in recent years. Increased detection and control efforts are needed to prevent it from becoming endemic in more European regions and healthcare facilities.
The document discusses the global spread of the mcr-1 gene, which confers plasmid-mediated colistin resistance in Enterobacteriaceae. This poses a substantial public health risk as it limits treatment options for multidrug-resistant infections. Options for response include improved detection of mcr-1 via laboratory methods like PCR and whole genome sequencing, enhanced surveillance programs, infection control measures in healthcare settings, antimicrobial stewardship, and reducing colistin use in animals to prevent further spread. A One Health approach combining human and veterinary medicine is needed to monitor mcr-1 in food and the environment.
Presentation from the ECDC expert consultation on Whole Genome Sequencing organised by the European Centre of Disease Prevention and Control - Stockholm, 19 November 2015
Presentation from the ECDC expert consultation on Whole Genome Sequencing organised by the European Centre of Disease Prevention and Control - Stockholm, 19 November 2015
Dag Harmsen presented on the evolvement and challenges of cgMLST for the harmonization of bacterial genome sequencing and analysis. Key points include:
- cgMLST (core genome multilocus sequence typing) involves identifying and comparing alleles across a fixed set of core genome genes and has been applied to outbreak investigation and global pathogen nomenclature.
- Tools for cgMLST analysis have been developed and improved to work on read, draft, and complete genome levels and allow scalable, additive analysis of single genes to whole genomes.
- Standardizing a hierarchical cgMLST-based approach and developing common nomenclature poses challenges but is important for microbial genotypic surveillance across laboratories and countries.
Presentation from the ECDC expert consultation on Whole Genome Sequencing organised by the European Centre of Disease Prevention and Control - Stockholm, 19 November 2015
Presentation from the ECDC expert consultation on Whole Genome Sequencing organised by the European Centre of Disease Prevention and Control - Stockholm, 19 November 2015
Presentation from the ECDC expert consultation on Whole Genome Sequencing organised by the European Centre of Disease Prevention and Control - Stockholm, 19 November 2015
This document summarizes discussions from several sessions of a meeting on antimicrobial resistance and healthcare-associated infections. Key points include:
- Most countries submit antimicrobial consumption data close to the deadline, and there are specific rules for who can access and publish the data.
- It is important but challenging to compare hospital antimicrobial consumption data between countries due to differences in how data is collected. Both defined daily doses and packages are needed for comparison.
- A pilot hospital-based antimicrobial consumption survey was proposed to collect additional data starting in late 2015, but the protocol requires further review and clarification before implementation.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Validation studies are essential to accurately assess the sensitivity, specificity, and predictive values of point prevalence surveys (PPS) of healthcare-associated infections (HAI). Previous validation studies of PPS have shown varied results, underscoring the need for formal evaluations. Without validation, true HAI prevalence is unknown and differences between locations cannot be properly investigated. International organizations can help support national validation efforts to improve HAI surveillance.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
This document contains forms and instructions for conducting a point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. The forms collect data at the hospital, ward, patient, and national/regional level. Hospital data includes bed numbers, staffing levels, infection control activities and organizational culture. Ward data includes bed numbers, hand hygiene infrastructure. Patient data collects infection details, antimicrobial use, and patient characteristics for those with infections or receiving antibiotics. National data provides healthcare system context. The forms standardize data collection to allow prevalence comparisons across settings.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
More from European Centre for Disease Prevention and Control (ECDC) (20)
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Cell Therapy Expansion and Challenges in Autoimmune Disease
ECDC ESAC-Net update. Klaus Weist (ECDC)
1. 3rd Joint Meeting of the Antimicrobial Resistance and
Healthcare-Associated Infections (ARHAI) Networks
What happened since the last annual
meeting with ESAC-Net?
Klaus Weist*, Arno Muller (Contractor to ECDC) for the
ARHAI Programme, European Centre for Disease Prevention and Control
Stockholm, 11‒13 February 2015 *Conflict of interests - none to disclose
Organised jointly with
2. 2
ESAC-Net Operational Contact Points, National Focal Points,
Coordination Committee Members in the ESAC-Net sessions
Country First Name Last name
Austria Gerhard FLUCH
Austria Reinhild STRAUSS
Belgium Anne INGENBLEEK
Belgium Katrien LATOUR
Bulgaria Bozhana TODOROVA
Croatia Marina PAYERL-PAL
Croatia Damijan DEBELEC
Czech Republic Jiří VLČEK
Czech Republic Tatiana BELKINA
Denmark Maja LAURSEN
Denmark Robert Leo SKOV
Estonia Katrin KURVITS
Estonia Ly ROOTSLANE
Finland Jaana VUOPIO
Finland Tinna VOIPIO
France Philippe CAVALIÉ
France Catherine DUMARTIN
Germany Birgitta SCHWEIKERT
Germany Muna ABU SIN
Greece Flora KONTOPIDOU
Greece Paraskevi TSONOU
Hungary Ria BENKŐ
Hungary Szilvia NYOLCZAS
Iceland Thorolful GUDNASON
Ireland Catherine MANNION
Ireland Ajay OZA
Latvia Elīna DIMIŅA
Lithuania Akvilė KENSTAVIČIENĖ
Lithuania Rolanda VALINTĖLIENĖ
Luxembourg Marcel BRUCH
Malta Peter ZARB
Norway Irene LITLESKARE
Norway Hege SalvesenBLIX
Poland Waleria HRYNIEWICZ
Poland Anna OLCZAK-PIEŃKOWSKA
Portugal Ana SILVA
Romania Lavinia CiprianaZOTA
Slovenia Milan CIŽMAN
Slovenia Tom BAJEC
Spain José CAMPOS
Spain César DE LA FUENTE
Sweden Jenny HELLMAN
Sweden Magdalena PRIOUX
United Kingdom Susan HOPKINS
United Kingdom Maggie HEGINBOTHOM
ESAC-Net CC Arno MULLER
ESAC-Net CC Theo VERHEIJ
Observer Mike SHARLAND
Observer Kari GRAVE
Observer Hanne BAK PEDERSEN
Presenter Ron POLK
Presenter Ann VERSPORTEN
Presenter Carlo GAGLIOTTI
3. 3
ESAC-Net Operational Contact Points, National Focal Points,
Coordination Committee Members in the ESAC-Net sessions
Country First Name Last name
Austria Gerhard FLUCH
Austria Reinhild STRAUSS
Belgium Anne INGENBLEEK
Belgium Katrien LATOUR
Bulgaria Bozhana TODOROVA
Croatia Marina PAYERL-PAL
Croatia Damijan DEBELEC
Czech Republic Jiří VLČEK
Czech Republic Tatiana BELKINA
Denmark Maja LAURSEN
Denmark Robert Leo SKOV
Estonia Katrin KURVITS
Estonia Ly ROOTSLANE
Finland Jaana VUOPIO
Finland Tinna VOIPIO
France Philippe CAVALIÉ
France Catherine DUMARTIN
Germany Birgitta SCHWEIKERT
Germany Muna ABU SIN
Greece Flora KONTOPIDOU
Greece Paraskevi TSONOU
Hungary Ria BENKŐ
Hungary Szilvia NYOLCZAS
Iceland Thorolful GUDNASON
Ireland Catherine MANNION
Ireland Ajay OZA
Latvia Elīna DIMIŅA
Lithuania Akvilė KENSTAVIČIENĖ
Lithuania Rolanda VALINTĖLIENĖ
Luxembourg Marcel BRUCH
Malta Peter ZARB
Norway Irene LITLESKARE
Norway Hege SalvesenBLIX
Poland Waleria HRYNIEWICZ
Poland Anna OLCZAK-PIEŃKOWSKA
Portugal Ana SILVA
Romania Lavinia CiprianaZOTA
Slovenia Milan CIŽMAN
Slovenia Tom BAJEC
Spain José CAMPOS
Spain César DE LA FUENTE
Sweden Jenny HELLMAN
Sweden Magdalena PRIOUX
United Kingdom Susan HOPKINS
United Kingdom Maggie HEGINBOTHOM
ESAC-Net CC Arno MULLER
ESAC-Net CC Theo VERHEIJ
Observer Mike SHARLAND
Observer Kari GRAVE
Observer Hanne BAK PEDERSEN
Presenter Ron POLK
Presenter Ann VERSPORTEN
Presenter Carlo GAGLIOTTI
4. 4
What happened since the last annual
meeting with ESAC-Net?
2nd ARHAI Networks Meeting on 26-28 Nov. 2012, Berlin
Status of participating countries
Report publications and the interactive database
Coordination Committee
Cooperation with other partners
ESAC-Net sessions during the next days
10th Annual Meeting
in Riga, Latvia, May 2011.
Introducing ESAC-Net
5. 5
Community antimicrobial consumption:
EU/EEA countries reporting for 2013
MT
Non-participating countries
Countries reporting community antimicrobial consumption*
PT
ES
UK
FR
IT
DE
NO
FI
LT
AT
HU
IE
IS
SE
DK
BE
LU
NL
EE
LV
PL
CZ
RO
BG
EL
CY
SI
SK
HR
Participating countries not reporting data
ESAC-Net participating countries
6. 6
Hospital sector antimicrobial consumption:
EU/EEA countries reporting for 2013
PT
ES
UK
FR
IT
DE
NO
FI
LT
AT
HU
IE
IS
SE
DK
BE
LU
NL
EE
LV
PL
CZ
RO
BG
EL
CY
SI
SK
HR
MT
Non-participating countries
Countries reporting community antimicrobial consumption*
Participating countries not reporting data
ESAC-Net participating countries
7. 7
Number of EU/EEA countries reporting data
Community
Hospital sector
ATC
group
Year
97 98 99 00 01 02 03 04 05 06 07 08 09 10* 11* 12* 13*
J01 10 12 12 12 14 17 15 17 15 15 16 16 16 18 17 20 19
D01B
A &
J02
9 14 15 14 17 16 18 17
J05
3 7 10 12 16 15 16 15
ATC
group
Year
97 98 99 00 01 02 03 04 05 06 07 08 09 10* 11* 12* 13*
J01 14 20 22 21 23 25 24 25 25 26 28 28 29 27 29 30 28
D01B
A &
J02
17 22 22 24 23 25 25 23
J05
7 13 17 21 23 24 24 23
*: data reported to ESAC-Net as of Feb. 2015 1997-09: ESAC project data
12. 12
ESAC-Net Coordination Committee (CC)
and cooperation with other partners
4 physical CC meetings
ECCMID 2014 presentation in Barcelona
(integrated analyses of glycopeptide consumption/resistance)
WHO/Euro project on surveillance of antimicrobial consumption
European Surveillance of Veterinarian Consumption (ESVAC) project
Joint Interagency Antimicrobial Consumption and Resistance
Analysis (JIACRA) Report
13. 13
A true story on needs
Needs assessment
1. Cold water needed from the start?
2. Warm water needed from the start?
3. Bad quality of flowers?
4. A clear case for disinfectants?
5. A clear case for antibiotics?
After 1.5 hours
1. Just fresh tap water refilled
(no need for antibiotics)
14. 14
3rd ARHAI Networks Meeting 11‒13 Feb. 2015
ESAC-Net session 5, 9, 10 and 16
(5) ESAC-Net
Moderators: Ria Benkő (HU), Oza Ajay (IE)
ESAC-Net data collection – Meta data – Quiz
Hospital sector I - Hospital sector definition
(9) Hospital-based surveillance
Moderators: Jiří Vlček (CZ), Elina Dimiņa (LV)
Experiences national systems – Antimicrobial stewardship indicators
Draft protocol for a pilot survey
(10) Community antimicrobial consumption
Moderators: Phillip Cavalié (FR), Theo Verheij (NL)
2013 data – broad- narrow-spectrum antibiotics – age and gender
Indicator packages per 1000 inhabitants and per day
(16) Cooperation and planning
Moderators: José Campos (ES), Rolanda Valinteliene (LT)
WHO/Euro – TATFAR - ESVAC
Future ESAC-Net outputs (Atlas of infectious diseases)